^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Squamous Non-Small Cell Cancer

    Related cancers:
    20h
    Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) (clinicaltrials.gov)
    P3, N=390, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Oct 2026 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement
    |
    erlotinib
    1d
    Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=16, Not yet recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Dec 2029 --> Jun 2030 | Initiation date: Jan 2026 --> Jun 2027 | Trial primary completion date: Dec 2028 --> Jun 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    EGFR mutation • EGFR L861Q • EGFR G719X
    |
    carboplatin • pemetrexed • zipalertinib (CLN-081)
    1d
    LIBRA: A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=278, Recruiting, AstraZeneca | Trial primary completion date: Mar 2027 --> Apr 2029
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Cyramza (ramucirumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)
    1d
    A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, University of Chicago
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CTAG1B (Cancer/testis antigen 1B)
    |
    HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    cyclophosphamide • decitabine • Proleukin (aldesleukin)
    1d
    Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC. (PubMed, ESMO Open)
    PACIFIC-R provides mature data on OS and rwPFS from a large, real-world cohort, supporting consolidation durvalumab as a standard of care in this setting.
    Journal • Real-world evidence • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab)
    3d
    Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, Shanghai Huaota Biopharmaceutical Co., Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed
    6d
    A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=450, Active, not recruiting, TJ Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)
    6d
    A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, TJ Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • carboplatin • gemcitabine • Tyvyt (sintilimab) • pemetrexed • uliledlimab (TJD5)
    6d
    STAR-121: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1021, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • ALK mutation • RET mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    6d
    Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiation and Immunotherapy. (PubMed, J Thorac Oncol)
    KRAS mutant non-sq LA-NSCLC is associated with inferior outcomes, largely driven by increased distant and brain metastases. Tumors with concurrent CDKN2A and/or STK11 alterations had the poorest outcomes. These findings support the evaluation of KRAS inhibitors in this high-risk stage III population.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    KRAS mutation • STK11 mutation • KRAS wild-type • RAS wild-type
    |
    Imfinzi (durvalumab)
    7d
    A study evaluating the efficacy and safety of aumolertinib mesylate as first-line therapy in patients with EGFR-mutated stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) complicated by chronic obstructive pulmonary disease (COPD) (ChiCTR2600117077)
    P=N/A, N=51, Not yet recruiting, Tianjin Chest Hospital; Tianjin Chest Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Ameile (aumolertinib)
    7d
    Evaluating the Efficacy and Safety of Trilaciclib in Patients Receiving First-line Sintilimab Plus Chemotherapy for Advanced Driver Gene-negative Non-squamous Non-Small Cell Lung Cancer (ChiCTR2600117016)
    P=N/A, N=80, Not yet recruiting, Shengjing Hospital of China Medical University; Shengjing Hospital of China Medical University
    New trial
    |
    carboplatin • Tyvyt (sintilimab) • pemetrexed • Cosela (trilaciclib)